NETWORK META-ANALYSIS (NMA) TO ASSESS RELATIVE EFFICACY MEASURED AS PERCENTAGE OF PATIENTS TREATED TO HBA1C TARGET WITH CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (M ...
Author(s)
Taieb V1, Pacou M2, Schroeder M3, Schubert A4, Nielsen AT5
1Amaris, London, UK, 2Amaris, Paris, France, 3Janssen UK, High Wycombe, UK, 4Janssen-Cilag Poland, Warsaw, Poland, 5Janssen-Cilag A/S, Birkerød, Denmark
OBJECTIVES: The growing prevalence of T2DM in Europe poses a significant economic and healthcare burden, mainly due to diabetes-related complications. Maintaining HbA1c below 7% has been shown to reduce the risk of complications in the longer term. In the absence of direct evidence comparing sodium glucose co-transporter 2 (SGLT2) inhibitors, indirect comparisons are needed to inform clinical and policy decisions. This analysis assessed the proportion of patients reaching the defined HbA1c goal of less than 7% with canagliflozin versus dapagliflozin and empagliflozin added to MET+SU. METHODS: A systematic literature review identified 14 randomised controlled trials, which were used to perform a Bayesian NMA to estimate the relative efficacy of canagliflozin added to MET+SU at 26±4 weeks. Relative efficacy was evaluated based on odds ratios (ORs) of the proportions of patients reaching the HbA1c target and Bayesian pairwise probabilities (P). Interpretation of results was based on ORs and P, where P≤30% indicated a smaller effect and P≥70% a larger effect. RESULTS: Canagliflozin dapagliflozin 10 mg and empagliflozin 25 mg (ORs of 1.12 [P=60%] and 0.94 [P=44%], respectively), and higher odds versus empagliflozin 10 mg (OR of 1.26 [P=73%]). Patients treated with canagliflozin dapagliflozin 10 mg and empagliflozin 25 and 10 mg (ORs of 2.03 [P=94%], 1.71 [P=93%], and 2.29 [P=99%], respectively). CONCLUSIONS: This NMA of add-on therapies to MET+SU suggests that the odds of achieving HbA1c<7% at 26 weeks were at least similar for canagliflozin
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PDB5
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Diabetes/Endocrine/Metabolic Disorders